CODA 001

Drug Profile

CODA 001

Alternative Names: Antisense deoxynucleotide oligomer - OcuNexus Therapeutics; Antisense oligonucleotide compound - OcuNexus Therapeutics; CODA001; Nexagon

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CoDa Therapeutics (NZ); CoDa Therapeutics Inc
  • Developer CoDa Therapeutics Inc; OcuNexus Therapeutics
  • Class Antisense oligonucleotides; Antiulcers
  • Mechanism of Action Gap junction modulators; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wounds
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wounds
  • No development reported Diabetic foot ulcer; Leg ulcer

Most Recent Events

  • 02 Oct 2018 CODA 001 is still in phase-II clinical trials in Wounds in USA (Topical)
  • 02 Oct 2018 Eyevance Pharmaceuticals plans a pivotal trial for Wounds (persistent corneal epithelial defect) in first quarter of 2019.
  • 25 Jul 2018 CoDa Therapeutics is now called OcuNexus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top